Construction of a Cohort of Elderly Patients With Atrial Fibrillation in Rural China
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age65-80
SponsorJiangsu Taizhou People's Hospital
About this trial
Atrial fibrillation (AF) is a common arrhythmia in aging populations and is strongly associated with an increased risk of heart failure (HF) and adverse cardiovascular outcomes. However, early detection of HF among patients with AF remain inadequate in rural settings. This study aims to screen for HF among older adults with AF in rural China and to conduct long-term follow-up in order to observe the disease progression in patients with AF.
This study will recruit at least 2,500 elderly individuals aged between 65 and 80 years, with confirmed diagnoses of AF, residing in rural areas. Participants will undergo HF screening using NT-proBNP testing and echocardiographic assessment. Additionally, data will be collected on electrocardiographic signals, seismocardiography, voice, and demographic characteristics. Following data collection, participants will be followed up every three months to monitor the incidence and progression of HF as well as the occurrence of adverse cardiovascular events.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Permanent residents with local household registration in rural China.
Aged 65-80 years.
Electrocardiogram confirmation of AF or possession of a diagnostic certificate for AF issued by a specialist.
Willing to participate in HF screening.
Disqualifiers
Expected life expectancy of less than 3 months.
Severe renal insufficiency (Ccr < 30ml/min) or ongoing dialysis treatment.
Cardiac insufficiency secondary to correctable causes, including hyperthyroid heart disease, anemic heart disease, or uncorrected congenital heart disease.
Indications for pacemaker implantation without having undergone implantation.
Trial population
The study population is rural-dwelling older adults aged 65 to 80 years with confirmed atrial fibrillation in China. Participants are required to undergo heart failure screening and provide informed consent. Individuals with severe comorbidities or conditions that may interfere with study participation will be excluded.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Composite endpoint
a composite of cardiovascular mortality, all strokes (ischemic or hemorrhagic stroke), hospitalization due to worsening of HF or acute coronary syndrome (ACS), and emergency visits due to AF
Time frame
through study completion, an average of 3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov